These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 17971091)

  • 1. Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.
    Snoeck E; Hadziyannis SJ; Puoti C; Swain MG; Berg T; Marcellin P; Zarski JP; Jorga K; Zeuzem S
    Liver Int; 2008 Jan; 28(1):61-71. PubMed ID: 17971091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
    Calleja JL; García-Samaniego J; Ruiz-Antorán B; Trapero M; Morillas R; de la Revilla J; Erdozaín JC; Espinosa MD; Suárez D; Solá R; Romero-Gómez M; Baños F; Alvarez MA;
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1705-10. PubMed ID: 22742958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E; Wade JR; Duff F; Lamb M; Jorga K
    Br J Clin Pharmacol; 2006 Dec; 62(6):699-709. PubMed ID: 17118125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
    Zeuzem S; Rodríguez-Torres M; Rajender Reddy K; Marcellin P; Diago M; Craxi A; Pockros P; Rizzetto M; Bernstein D; Shiffman ML; Lin A; Tatsch F; Hadziyannis S
    J Viral Hepat; 2012 Nov; 19(11):766-74. PubMed ID: 23043383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.
    Bini EJ; Mehandru S
    Aliment Pharmacol Ther; 2006 Mar; 23(6):777-85. PubMed ID: 16556180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study.
    Puoti C; Barbarini G; Picardi A; Romano M; Pellicelli A; Barlattani A; Mecenate F; Guarisco R; Costanza OM; Spilabotti L; Bellis L; Bonaventura ME; Dell' Unto O; Elmo MG; Nicolini AM; Nosotti L; Soccorsi F;
    J Viral Hepat; 2011 Jun; 18(6):393-9. PubMed ID: 20546499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
    Arora S; O'Brien C; Zeuzem S; Shiffman ML; Diago M; Tran A; Pockros PJ; Reindollar RW; Gane E; Patel K; Wintfeld N; Green J
    J Gastroenterol Hepatol; 2006 Feb; 21(2):406-12. PubMed ID: 16509866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.
    Puoti C; Pellicelli AM; Romano M; Mecenate F; Guarisco R; Barbarini G; Mazzoni E; Spilabotti L; Bellis L; Paglia F; Barlattani A; Picardi A; Paffetti A; Bonaventura ME; Nosotti L; Mitidieri O; Dell'Unto O; Villani R; Dell'Unto C; Morrone A; Soccorsi F;
    Liver Int; 2009 Nov; 29(10):1479-84. PubMed ID: 19422478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
    Ferenci P; Aires R; Ancuta I; Arohnson A; Cheinquer H; Delic D; Gschwantler M; Larrey D; Tallarico L; Schmitz M; Tatsch F; Ouzan D
    Liver Int; 2014 Nov; 34(10):1550-9. PubMed ID: 24329937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study.
    Balart LA; Lisker-Melman M; Hamzeh FM; Kwok A; Lentz E; Rodriguez-Torres M;
    Am J Gastroenterol; 2010 Oct; 105(10):2177-85. PubMed ID: 20389293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.
    Rodriguez-Torres M; Govindarajan S; Diago M; Morgan T; Anand B; Barange K; Suter F; Lin A; Hooper G; Shiffman M
    Liver Int; 2009 Feb; 29(2):237-41. PubMed ID: 18710427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.
    Keating GM; Plosker GL
    Drugs; 2005; 65(4):521-36. PubMed ID: 15733013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
    Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
    Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
    Sánchez-Tapias JM; Diago M; Escartín P; Enríquez J; Romero-Gómez M; Bárcena R; Crespo J; Andrade R; Martínez-Bauer E; Pérez R; Testillano M; Planas R; Solá R; García-Bengoechea M; Garcia-Samaniego J; Muñoz-Sánchez M; Moreno-Otero R;
    Gastroenterology; 2006 Aug; 131(2):451-60. PubMed ID: 16890599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment.
    Nakamura M; Kanda T; Miyamura T; Wu S; Nakamoto S; Yokosuka O
    Int J Med Sci; 2013; 10(8):1015-21. PubMed ID: 23801888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
    Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.